Synthetic engineered bacteria for cancer therapy
INTRODUCTION: Cancer mortality worldwide highlights the urgency for advanced therapeutic methods to fill the gaps in conventional cancer therapies. Bacteriotherapy is showing great potential in tumor regression due to the motility and colonization tendencies of bacteria. However, the complicated in vivo environment and tumor pathogenesis hamper the therapeutic outcomes. Synthetic engineering methods endow bacteria with flexible abilities both at the extracellular and intracellular levels to meet treatment requirements. In this review, we introduce synthetic engineering methods for bacterial modifications. We highlight the recent progress in engineered bacteria and explore how these synthetic methods endow bacteria with superior abilities in cancer therapy. The current clinical translations are further discussed. Overall, this review may shed light on the advancement of engineered bacteria for cancer therapy.
AREAS COVERED: Recent progress in synthetic methods for bacterial engineering and specific examples of their applications in cancer therapy are discussed in this review.
EXPERT OPINION: Bacteriotherapy bridges the gaps of conventional cancer therapies through the natural motility and colonization tendency of bacteria, as well as their synthetic engineering. Nevertheless, to fulfill the bacteriotherapy potential and move into clinical trials, more research focusing on its safety concerns should be conducted.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
---|---|
Enthalten in: |
Expert opinion on drug delivery - 20(2023), 7 vom: 01. Juli, Seite 993-1013 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Gong, Tong [VerfasserIn] |
---|
Links: |
---|
Themen: |
Bacteria |
---|
Anmerkungen: |
Date Completed 02.11.2023 Date Revised 02.11.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1080/17425247.2023.2241367 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM359976379 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM359976379 | ||
003 | DE-627 | ||
005 | 20231226082023.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1080/17425247.2023.2241367 |2 doi | |
028 | 5 | 2 | |a pubmed24n1199.xml |
035 | |a (DE-627)NLM359976379 | ||
035 | |a (NLM)37497622 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Gong, Tong |e verfasserin |4 aut | |
245 | 1 | 0 | |a Synthetic engineered bacteria for cancer therapy |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 02.11.2023 | ||
500 | |a Date Revised 02.11.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a INTRODUCTION: Cancer mortality worldwide highlights the urgency for advanced therapeutic methods to fill the gaps in conventional cancer therapies. Bacteriotherapy is showing great potential in tumor regression due to the motility and colonization tendencies of bacteria. However, the complicated in vivo environment and tumor pathogenesis hamper the therapeutic outcomes. Synthetic engineering methods endow bacteria with flexible abilities both at the extracellular and intracellular levels to meet treatment requirements. In this review, we introduce synthetic engineering methods for bacterial modifications. We highlight the recent progress in engineered bacteria and explore how these synthetic methods endow bacteria with superior abilities in cancer therapy. The current clinical translations are further discussed. Overall, this review may shed light on the advancement of engineered bacteria for cancer therapy | ||
520 | |a AREAS COVERED: Recent progress in synthetic methods for bacterial engineering and specific examples of their applications in cancer therapy are discussed in this review | ||
520 | |a EXPERT OPINION: Bacteriotherapy bridges the gaps of conventional cancer therapies through the natural motility and colonization tendency of bacteria, as well as their synthetic engineering. Nevertheless, to fulfill the bacteriotherapy potential and move into clinical trials, more research focusing on its safety concerns should be conducted | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Bacteria | |
650 | 4 | |a Bacteriotherapy | |
650 | 4 | |a cancer therapy | |
650 | 4 | |a delivery | |
650 | 4 | |a synthetic engineering methods | |
700 | 1 | |a Wu, Jinhui |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug delivery |d 2004 |g 20(2023), 7 vom: 01. Juli, Seite 993-1013 |w (DE-627)NLM159019028 |x 1744-7593 |7 nnns |
773 | 1 | 8 | |g volume:20 |g year:2023 |g number:7 |g day:01 |g month:07 |g pages:993-1013 |
856 | 4 | 0 | |u http://dx.doi.org/10.1080/17425247.2023.2241367 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 20 |j 2023 |e 7 |b 01 |c 07 |h 993-1013 |